Australia's most trusted
source of pharma news
Tuesday, 21 January 2025
Posted 2 April 2024 AM
MSD has scored the first nod for its blood pressure med Winrevair in the US, positioning the company to start its run at blockbuster status.
Winrevair, also known as sotatercept, is the first disease-modifying treatment for adults with pulmonary arterial hypertension (PAH) and is anticipated to make MSD one of the biggest players in the cardiovascular market in coming years.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.